ArticleFrontiers in bioengineering and biotechnology2025
Engineering bioactive mineralized tumor cells for tumor immunotherapy.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Manganese Ion-Based NanoPlatforms for Tumor Theranostics.Advanced healthcare materials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Whole-cell tumor vaccines are advantageous because of their ability to induce a broad and multifaceted immune response through the presentation of a wide range of tumor antigens, thereby enhancing the ability of the immune system to recognize and target cancerous cells. Method: In this study, we present a multifunctional vaccine that consists of manganese-mineralized tumor cells and positively charged polymer-immobilized CpG. The Mn Result: As a consequence, the engineered vaccine derived from B16F10 cells exhibited a pronounced tumor-suppressive effect, reducing the tumor volume to approximately one-fifth of that in the control group, and significantly extending survival to day 30 in B16F10 tumor-bearing mice. This superior therapeutic outcome is associated with enhanced activation of dendritic cells, increased infiltration of NK and CD8 Discussion: Together, our study highlights the immense potential of engineering bioactive mineralized tumor cells to facilitate whole-cell tumor vaccine-based immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.